EGFR and non-small cell lung carcinoma: In EGFR-mutant non-small cell lung cancer (NSCLC), resistance to tyrosine kinase inhibitors (TKIs) is associated with the epigenetic silencing of the tumor-suppressive miR-483-3p [179].